Takeda Partners With Point32Health to Offer Value-Based Oncology Program in US
Takeda has partnered with Point32Health in a new value-based oncology program. Alunbrig, used in non-small cell lung cancer, is the [...]
Merck’s Keytruda Expected to Hit $17 Billion Yearly Revenue
Merck’s Keytruda continues to generate billion-dollar sales. The oncology drug reached $4.5 billion of sales in the third quarter, making [...]
[Podcast] Understanding the Limitations of Proposed Drug Pricing Reforms
Terry Wilcox of the Patients Rising Podcast interviewed Chief Science Policy Officer at Global Healthy Living Foundation Robert Popovian in [...]
Two New PBMs Promise Patient Centricity and Pricing Transparency
EmsanaRx and Mark Cuban’s Cost Plus startup are the latest pharmacy benefit management (PBM) companies promising transparency and a patient-centered [...]
EQRx Partners With Two Healthcare Payers To Reduce Drug Costs
EQRx has announced partnerships with the National Health Service and Blue Cross Blue Shield North Carolina in England. The biotech [...]
New Drug Pricing Legislation Proposal Protects Small Biotech and Caps Prices
A new pricing policy would set limits on costs for seniors, protect small biotechs, and discount the prices of rapidly [...]
EQRx Partners With Two Payers to Reduce Drug Costs, Seeks Chinese Approval of Low Cost Oncology Drugs
EQRx has formed partnerships with two healthcare insurance companies to reach its ambitious goal of reducing drug costs. The company [...]
CMS Penalties for Hospitals Failing Transparency Requirements Set for January 2022
The Centers for Medicare & Medicaid (CMS) has detailed fees for hospitals failing to meet transparency guidelines. The penalties will [...]
Biden Administration Rethinks Medicare Negotiation
Democratic attempts to curb drug prices have been hindered by conflict within the party as well as external lobbying by [...]
Pharma Gears Up for Pricing Battle as Democrats Scale Back Legislation
Democrats are gradually reducing the scope of legislation intended to reduce drug prices. The pharmaceutical industry has voiced its opposition [...]
Biogen Reports Low Aduhelm Sales Amid Medicare Uncertainty
Biogen reported low sales of Alzheimer’s drug Aduhelm. Although the Centers for Medicare and Medicaid (CMS) are unable to negotiate [...]
Value in Health Editors Issue Call for Papers on Drug Costs
The editors of Value in Health have issued a call for papers related to prescription drug costs throughout the product [...]
New Podcast on Drug Pricing Reform Myths and Realistic Solutions
A new episode of the Patients Rising Podcast series is now available. In this installment, Chief Science Policy Officer at [...]
Mark Cuban Enters Convoluted PBM Market, Promises Lower Prescription Drug Prices
Two new groups have entered the pharmacy benefit manager (PBM) market: Mark Cuban and a coalition of employers. The Mark [...]
Eli Lilly CEO Shares Thoughts on How Medicare Pricing Measures Could Impact Innovation
Eli Lilly CEO David Ricks shared his thoughts on how policies intended to lower drug prices would negatively impact pharmaceutical [...]
Four Health Strategies Help Employers Reduce Costs
A new article highlights four approaches that can help forward-looking employers reduce the costs of healthcare. These strategies include advanced [...]
Three Decades of Democratic Drug Price Control Efforts Face Uncertainty
More than thirty years of drug price regulation efforts by Democrats are facing uncertainty as efforts to pass legislation allowing [...]
EURIPID Survey Shines Spotlight on Drug Price Transparency and Confidential Payer-Pharma Agreements
A recent article, published in Health Policy, highlights the use of confidential managed-entry agreements (MEAs) between payers and pharma throughout [...]
Why Did Medicare Squander $600 Million on Efficacy-Free Cancer Drugs?
According to a new JAMA report, Medicare spent almost $600 million in three years on drugs used in oncology treatments. [...]
CMMI Director Discusses Aduhelm Coverage
Center for Medicare and Medicaid Innovation (CMMI) Director Elizabeth Fowler recently discussed Biogen’s Aduhelm drug. She noted that Congress first needs [...]
American Drug Market Is a Pharma Cash Cow
A recent report considers the prescription drug prices of 20 top-selling drugs—both in the United States and worldwide. The trend [...]
New Whitepaper Highlights CMS-Compliant Price Comparison Tool
RxSavings Solutions is offering a new whitepaper that highlights its real-time benefit tool (RTBT) that compares drug prices. The pricing [...]
New Prescryptive Health PBM Reduces Drug Costs Using EHR Data and Promotes Transparency
Amid growing criticism regarding pharmacy benefit managers (PBMs), one new startup is entering the crowded space. Prescryptive Health aims to [...]
Employer Healthcare Costs Will Increase 5% in 2022 as the COVID-19 Pandemic Continues
A recent report released by Willis Towers Watson notes an expected 5% increase in healthcare costs in 2022. Premiums and [...]
ICER VP of Research Recognized as Emerging Health Leader, Seeks to Improve Health Equity
Foluso Agboola, a Nigerian researcher who pursued her training at Harvard before joining the Institute for Clinical and Economic Review [...]